AngioDynamics Files 8-K on Security Holder Votes
Ticker: ANGO · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
Related Tickers: ANGI
TL;DR
ANGI filed an 8-K for shareholder votes on Nov 10th.
AI Summary
AngioDynamics, Inc. filed an 8-K on November 12, 2025, reporting on matters submitted to a vote of its security holders. The filing date for this report is November 10, 2025. The company is incorporated in Delaware and its principal executive offices are located at 14 Plaza Drive, Latham, New York.
Why It Matters
This filing indicates that AngioDynamics, Inc. is engaging in corporate governance activities requiring shareholder approval, which could impact the company's strategic direction or operational decisions.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- AngioDynamics, Inc. (company) — Registrant
- 14 Plaza Drive, Latham, New York 12110 (location) — Principal Executive Offices
- November 10, 2025 (date) — Earliest event reported
- November 12, 2025 (date) — Filing date
FAQ
What specific matters were submitted to a vote of AngioDynamics, Inc. security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 10, 2025.
What is the principal executive office address for AngioDynamics, Inc.?
The principal executive offices are located at 14 Plaza Drive, Latham, New York 12110.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for AngioDynamics, Inc.?
The Standard Industrial Classification (SIC) code for AngioDynamics, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-12 07:01:04
Key Financial Figures
- $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select
Filing Documents
- ef20058726_8k.htm (8-K) — 36KB
- 0001140361-25-041542.txt ( ) — 160KB
- ango-20251110.xsd (EX-101.SCH) — 4KB
- ango-20251110_lab.xml (EX-101.LAB) — 21KB
- ango-20251110_pre.xml (EX-101.PRE) — 16KB
- ef20058726_8k_htm.xml (XML) — 4KB
07 –
Item 5.07 – Submission of Matters to a Vote of Security Holders. (a) The Annual Meeting of Shareholders of AngioDynamics, Inc. ("AngioDynamics") was held on November 10, 2025. (b) Shareholders of AngioDynamics voted on the matters set forth below. 1. The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2028 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes: Nominee Votes For Withheld Broker Non-Votes James C. Clemmer 29,634,152 800,454 5,462,943 Michael E. Tarnoff, MD 29,245,896 1,188,710 5,462,943 2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the Votes for approval 35,727,186 Votes against 156,899 Abstentions 13,464 There were no broker non-votes for this item. 3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers was approved based upon the following votes: Votes for approval 28,357,782 Votes against 2,057,982 Abstentions 18,842 Broker non-votes 5,462,943 (c) Not applicable. (d) Not applicable. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: November 12, 2025 By: /s/ Lawrence T. Weiss Name: Lawrence T. Weiss Title: Senior Vice President, Chief Legal Officer and Corporate Secretary